Each capsule contains : 300 mg of gabapentin , USP .
Dosage and Use : See package insert for full prescribing information Store at 20 to 25 C ( 68 to 77 F ) ; excursions permitted to 15 to 30 C ( 59 to 86 F ) ) [ See USP Controlled Room Temperature ] .
Dispense in tight ( USP ) , child - resistant containers .
Pharmacist : Please dispense with medication guide provided separately Highlights of Prescribing Information These highlights do not include all the information needed to use gabapentin capsules safely and effectively .
See full prescribing information for gabapentin capsules .
GABAPENTIN capsules , USP for oral use Initial U . S . Approval : 1993 FULL PRESCRIBING INFORMATION : CONTENTS INDICATIONS AND USAGE Gabapentin capsules , USP , are indicated for : - management of postherpeticneuralgia in adults - Adjunctive therapy in the treatment of partial onset seizures , with and without secondary generalization , in adults and pediatric patients 3 years and older with epilepsy DOSAGE AND ADMINISTRATION Gabapentin capsules , USP are given orally with or without food .
Gabapentin capsules , USP should be swallowed whole with plenty of water .
DOSAGE FORMS AND STRENGTHS Capsules : • 100 mg ; white - white , opague hard gelatin capsules printed with " IP 101 " on both cap and body .
• 300 mg : buff - buff , opague hard gelatin capsules printed with " IP 102 " on both cap and body .
• 400 mg : light caramel - light caramel , opague hard gelatin capsules printed with " IP 103 " on both cap and body CONTRAINDICATIONS Gabapentin capsules , USP are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients .
WARNINGS AND PRECAUTIONS Drug Reaction with Eosinophilia and Systemic Symptoms ( DRESS ) Multiorgan Hypersensitivity Drug Reaction with with Eosinophilia and Systemic Symptoms ADVERSE REACTIONS The following severe adverse reactions are discussed in greater detail in other sections : Drug Reaction with Eosiniphilia and Systemic Syndrome ( DRESS ) Multiorgan DRUG INTERACTIONS Other Antiepileptic Drugs Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly co - administered antiepileptic drugs USE IN SPECIFIC POPULATIONS Pregnanacy - Pregnancy Category C : There are no adequate and well - controlled studies in pregnant women .
DRUG ABUSE AND DEPENDENCE Controlled Substance - Gabapentin is not a scheduled drug .
OVERDOSAGE A lethal dose of gabapentin was not identified in mice and rats receiving single oral doses as high as 8000 mg / kg .
DESCRIPTION The active ingredient in gabapentin capsules , USP is gabapentin which has the chemical name 1 - ( aminoethyl ) cyclohexaneacetic acid .
CLINICAL PHARMACOLOGY Mechanism of Action - The precise mechanisms by which gabapentin produces its analgesic and antiepileptic actions are unknown .
NONCLINICAL TOXICOLOGY Carcinogenesis , Mutagenesis , Impairment of Fertility - Gabapentin was adminstered orally to mice and rats in 2 - year carcinogenicity studies .
CLINICAL STUDIES Postherpetic Neuralgia Gabapentin was evaluated for the management of postherpetic neuralgia ( PHN ) in two randomized , double - blind , placebo - controlled multicenter studies .
HOW SUPPLIED / STORAGE AND HANDLING Gabapentin capsules , USP PATIENT COUNSELING INFORMATION [ MULTIMEDIA ] [ MULTIMEDIA ]
